Revolution Medicines (RVMD) Price & Analysis

Compare

470 Followers

RVMD Stock Chart & Stats

Day’s Range― - ―

52-Week Range$29.17 - $62.40

Previous CloseN/A

Volume180.68K

Average Volume (3M)2.14M

Market Cap

$8.30B

Enterprise Value$4.93B

Total Cash (Recent Filing)$2.14B

Total Debt (Recent Filing)$132.79M

Price to Earnings (P/E)―

Beta1.30

Next Earnings

Nov 05, 2025

EPS Estimate

-1.41

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.31

Shares Outstanding186,933,200

10 Day Avg. Volume2,540,205

30 Day Avg. Volume2,135,858

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.59

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-8.98

Enterprise Value/Ebitda-5.58

Forecast

1Y Price Target

$71.22

Price Target Upside63.57% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering16

Bulls Say, Bears Say

Bulls Say

Efficacy Of DaraxonrasibDaraxonrasib monotherapy achieved a 47% ORR and 89% DCR, while the combination with GnP showed a 55% ORR and 90% DCR, both surpassing common chemotherapeutic options.

Pipeline PotentialRevolution Medicines has built the broadest pipeline attacking cancer targets including a coveted multi-target 'pan' inhibitor, which is projected to be a significant revenue generator.

Bears Say

Competitive RisksThere is a risk that competitors' pan-KRAS could be equally effective but safer than Revolution Medicines' leading candidate.

Revolution Medicines News

Revolution Medicines price target raised to $71 from $70 at JPMorgan

JPMorgan raised the firm’s price target on Revolution Medicines (RVMD) to $71 from $70 and keeps an Overweight...

2d ago

RVMD

These 2 Stocks Could Be Prime Takeover Targets, According to Analysts

What began as a cautious ride earlier in the year has swelled into a full-blown bull market. The...

3d ago

JAMF

RVMD

Revolution Medicines resumed with a Strong Buy at Raymond James

Raymond James resumed coverage of Revolution Medicines (RVMD) with a Strong Buy rating and $72 price target The...

15d ago

RVMD

Revolution Medicines rises 14.2%

Revolution Medicines (RVMD) is up 14.2%, or $5.74 to $46.19. Published first on TheFly – the ultimate source...

16d ago

RVMD

Morning Movers: Kroger rises following second quarter results

Stock futures are slightly higher following inflation data that could influence the Federal Reserve’s next move. Producer price...

16d ago

CNC

Revolution Medicines announces results from daraxonrasib Phase 1 trials

Revolution Medicines (RVMD) on Wednesday announced clinical updates from its daraxonrasib Phase 1 clinical trials. The data focuses...

16d ago

RVMD

Revolution Medicines price target raised to $70 from $67 at Wells Fargo

Wells Fargo analyst Eva Fortea Verdejo raised the firm’s price target on Revolution Medicines (RVMD) to $70 from...

16d ago

RVMD

Leerink says competitor data suggest promising view for Revolution’s zoldonrasib

Leerink analyst Jonathan Chang says that following Verastem (VSTM)/GenFleet’s interim data presentation for their KRAS G12D inhibitor program,...

19d ago

RVMD

VSTM

Revolution Medicines initiated with a Buy at Truist

Truist initiated coverage of Revolution Medicines (RVMD) with a Buy rating and $99 price target The firm says...

22d ago

RVMD

Promising Position of Revolution Medicines’ Zoldonrasib Justifies Buy Rating

Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on RVMD stock, giving a Buy rating today....

16d ago

RVMD

Promising Potential of Daraxonrasib in Pancreatic Cancer Boosts Buy Rating for Revolution Medicines

Ami Fadia, an analyst from Needham, maintained the Buy rating on Revolution Medicines. The associated price target was...

16d ago

RVMD

Promising Clinical Trials and Strategic Design Drive Buy Rating for Revolution Medicines

Revolution Medicines, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Charles Zhu from...

16d ago

RVMD

Revolution Medicines Reports Promising Phase 1 Study Results

Revolution Medicines ( ($RVMD) ) just unveiled an announcement. On September 10, 2025, Revolution Medicines reported updates from...

16d ago

RVMD

Piper starts Revolution Medicines at Overweight on daraxonrasib potential

Piper Sandler analyst Kelsey Goodwin last night initiated coverage of Revolution Medicines (RVMD) with an Overweight rating and...

1M ago

RVMD

RVMD FAQ

What was Revolution Medicines’s price range in the past 12 months?

Revolution Medicines lowest stock price was $29.17 and its highest was $62.40 in the past 12 months.

What is Revolution Medicines’s market cap?

Revolution Medicines’s market cap is $8.30B.

When is Revolution Medicines’s upcoming earnings report date?

Revolution Medicines’s upcoming earnings report date is Nov 05, 2025 which is in 39 days.

How were Revolution Medicines’s earnings last quarter?

Revolution Medicines released its earnings results on Aug 06, 2025. The company reported -$1.31 earnings per share for the quarter, missing the consensus estimate of -$1.138 by -$0.172.

Is Revolution Medicines overvalued?

According to Wall Street analysts Revolution Medicines’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Revolution Medicines pay dividends?

Revolution Medicines does not currently pay dividends.

What is Revolution Medicines’s EPS estimate?

Revolution Medicines’s EPS estimate is -1.41.

How many shares outstanding does Revolution Medicines have?

Revolution Medicines has 186,933,200 shares outstanding.

What happened to Revolution Medicines’s price movement after its last earnings report?

Revolution Medicines reported an EPS of -$1.31 in its last earnings report, missing expectations of -$1.138. Following the earnings report the stock price went down -4.69%.

Which hedge fund is a major shareholder of Revolution Medicines?

Currently, no hedge funds are holding shares in RVMD

Revolution Medicines Stock Smart Score

Outperform

Fundamentals

Return on Equity

-46.61%

Trailing 12-Months

Asset Growth

34.35%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Revolution Medicines

Revolution Medicines, Inc. (RVMD) is a biotechnology company that operates in the pharmaceutical sector, focusing on the discovery and development of novel targeted therapies for cancer. The company is particularly known for its precision oncology approach, targeting specific genetic mutations and pathways that drive cancer growth and progression. Revolution Medicines' core products are centered around inhibiting critical signaling pathways, such as the RAS and mTOR pathways, which are implicated in various types of cancers.

Revolution Medicines (RVMD) Earnings & Revenues

Historic Earnings Reports

RVMD Company Deck

RVMD Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a generally positive outlook with significant progress in clinical trials and strategic financial partnerships. However, increased expenses and dependency on regulatory approvals present challenges.View all RVMD earnings summaries

RVMD Stock 12 Month Forecast

Average Price Target

$71.22

▲(63.57% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","81":"$81","44.25":"$44.3","56.5":"$56.5","68.75":"$68.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":71.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$71.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.91,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.91</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,44.25,56.5,68.75,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.53,42.643076923076926,45.75615384615385,48.86923076923077,51.98230769230769,55.09538461538462,58.208461538461535,61.32153846153846,64.43461538461538,67.5476923076923,70.66076923076923,73.77384615384615,76.88692307692307,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.53,41.96769230769231,44.40538461538462,46.84307692307692,49.28076923076923,51.71846153846154,54.15615384615384,56.59384615384615,59.03153846153846,61.46923076923077,63.90692307692308,66.34461538461538,68.78230769230768,{"y":71.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.53,39.40538461538462,39.28076923076923,39.15615384615385,39.03153846153846,38.90692307692308,38.78230769230769,38.65769230769231,38.53307692307692,38.40846153846154,38.28384615384615,38.15923076923077,38.03461538461538,{"y":37.91,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.63,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.17,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.8,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.74,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.95,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.89,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.53,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >